Trial: NCT02574078

Disease Type: Lung
Status: Open

Trial Information

A Master Protocol of Phase 2 Studies of Nivolumab in Advanced NSCLC: Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment, Alone or in Combination with Standard of Care Therapies (CHECKMATE 370)

Click here for more information

This trial is available at:

Methodist Estabrook Cancer Center
8303 Dodge Street, Suite 250, Omaha, NE 68114
Phone: 402-354-8124
Fax: 402-354-8127

Midwest Cancer Center – Legacy
17201 Wright Street, Suite 200, Omaha, NE 68130
Phone: 402-334-4773
Fax: 402-330-7463

Midwest Cancer Center – Papillion
611 Fenwick Drive, Papillion, NE 68046
Phone: 402-593-3141
Fax: 402-593-3145

For more information, please contact:

Trial: NCT01907100

Disease Type: Lung
Status: Open

Trial Information

Double blind, randomised, multicentre, phase II/III study of nintedanib in combination with pemetrexed/cisplatin followed by continuing nintedanib monotherapy versus placebo in combination with pemetrexed/cisplatin followed by continuing placebo monotherapy for the treatment of patients with unresectable malignant pleural mesothelioma

Click here for more information

This trial is available at:

Methodist Estabrook Cancer Center
8303 Dodge Street, Suite 250, Omaha, NE 68114
Phone: 402-354-8124
Fax: 402-354-8127

Midwest Cancer Center – Legacy
17201 Wright Street, Suite 200, Omaha, NE 68130
Phone: 402-334-4773
Fax: 402-330-7463

Midwest Cancer Center – Papillion
611 Fenwick Drive, Papillion, NE 68046
Phone: 402-593-3141
Fax: 402-593-3145

For more information, please contact:

Trial: NCT02154490

Disease Type: Lung
Status: Open

Trial Information

A Phase II/III Biomarker Driven Master Protocol for Second Line Therapy of Squamous Cell Lung Cancer

Click here for more information

This trial is available at:

Henry Lynch Cancer Center – Bergan
7500 Mercy Road, Suite 1300, Omaha, NE 68124
Phone: 402-393-3110
Fax: 402-393-4499

Methodist Estabrook Cancer Center
8303 Dodge Street, Suite 250, Omaha, NE 68114
Phone: 402-354-8124
Fax: 402-354-8127

Midwest Cancer Center – Legacy
17201 Wright Street, Suite 200, Omaha, NE 68130
Phone: 402-334-4773
Fax: 402-330-7463

Midwest Cancer Center – Papillion
611 Fenwick Drive, Papillion, NE 68046
Phone: 402-593-3141
Fax: 402-593-3145

For more information, please contact:

Trial: NCT02201992

Disease Type: Lung
Status: Open

Trial Information

A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Placebo for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein

Click here for more information

This trial is available at:

Henry Lynch Cancer Center – Bergan
7500 Mercy Road, Suite 1300, Omaha, NE 68124
Phone: 402-393-3110
Fax: 402-393-4499

Methodist Estabrook Cancer Center
8303 Dodge Street, Suite 250, Omaha, NE 68114
Phone: 402-354-8124
Fax: 402-354-8127

Midwest Cancer Center – Legacy
17201 Wright Street, Suite 200, Omaha, NE 68130
Phone: 402-334-4773
Fax: 402-330-7463

Midwest Cancer Center – Papillion
611 Fenwick Drive, Papillion, NE 68046
Phone: 402-593-3141
Fax: 402-593-3145

For more information, please contact:

Trial: NCT02193282

Disease Type: Lung
Status: Open

Trial Information

Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC) (ALCHEMIST)

Click here for more information

This trial is available at:

Henry Lynch Cancer Center – Bergan
7500 Mercy Road, Suite 1300, Omaha, NE 68124
Phone: 402-393-3110
Fax: 402-393-4499

Methodist Estabrook Cancer Center
8303 Dodge Street, Suite 250, Omaha, NE 68114
Phone: 402-354-8124
Fax: 402-354-8127

Midwest Cancer Center – Legacy
17201 Wright Street, Suite 200, Omaha, NE 68130
Phone: 402-334-4773
Fax: 402-330-7463

Midwest Cancer Center – Papillion
611 Fenwick Drive, Papillion, NE 68046
Phone: 402-593-3141
Fax: 402-593-3145

For more information, please contact:

Trial: NCT02194738

Disease Type: Lung
Status: Open

Trial Information

Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)

Click here for more information

This trial is available at:

Henry Lynch Cancer Center – Bergan
7500 Mercy Road, Suite 1300, Omaha, NE 68124
Phone: 402-393-3110
Fax: 402-393-4499

Methodist Estabrook Cancer Center
8303 Dodge Street, Suite 250, Omaha, NE 68114
Phone: 402-354-8124
Fax: 402-354-8127

Midwest Cancer Center – Legacy
17201 Wright Street, Suite 200, Omaha, NE 68130
Phone: 402-334-4773
Fax: 402-330-7463

Midwest Cancer Center – Papillion
611 Fenwick Drive, Papillion, NE 68046
Phone: 402-593-3141
Fax: 402-593-3145

For more information, please contact:

Trial: NCT01822496

Disease Type: Lung
Status: Open

Trial Information

A Randomized Phase II Study of Individualized Combined Modality Therapy for Stage III Non-Small Cell Lung Cancer (NSCLC)

Click here for more information

This trial is available at:

Methodist Estabrook Cancer Center
8303 Dodge Street, Suite 250, Omaha, NE 68114
Phone: 402-354-8124
Fax: 402-354-8127

For more information, please contact:

Trial: NCT00188734

Disease Type: Lung
Status: Open

Trial Information

Early Lung Cancer Detection Using Computed Tomography

Click here for more information

This trial is available at:

Methodist Estabrook Cancer Center
8303 Dodge Street, Suite 250, Omaha, NE 68114
Phone: 402-354-8124
Fax: 402-354-8127

For more information, please contact:

Trial: NCT00632853

Disease Type: Lung
Status: Open

Trial Information

Phase III Comparison of Thoracic Radiotherapy Regimens in Patients With Limited Small Cell Lung Cancer Also Receiving Cisplatin and Etoposide

Click here for more information

This trial is available at:

Henry Lynch Cancer Center – Bergan
7500 Mercy Road, Suite 1300, Omaha, NE 68124
Phone: 402-393-3110
Fax: 402-393-4499

Methodist Estabrook Cancer Center
8303 Dodge Street, Suite 250, Omaha, NE 68114
Phone: 402-354-8124
Fax: 402-354-8127

Midwest Cancer Center – Legacy
17201 Wright Street, Suite 200, Omaha, NE 68130
Phone: 402-334-4773
Fax: 402-330-7463

Midwest Cancer Center – Papillion
611 Fenwick Drive, Papillion, NE 68046
Phone: 402-593-3141
Fax: 402-593-3145

For more information, please contact:

Trial: NCT02438722

Disease Type: Lung
Status: Open

Trial Information

A Randomized Phase II/III Trial of Afatinib Plus Cetuximab Versus Afatinib Alone in Treatment-Naive Patients With Advanced, EGFR Mutation Positive Non-small Cell Lung Cancer (NSCLC)

Click here for more information

This trial is available at:

Henry Lynch Cancer Center – Bergan
7500 Mercy Road, Suite 1300, Omaha, NE 68124
Phone: 402-393-3110
Fax: 402-393-4499

Midwest Cancer Center – Legacy
17201 Wright Street, Suite 200, Omaha, NE 68130
Phone: 402-334-4773
Fax: 402-330-7463

Midwest Cancer Center – Papillion
611 Fenwick Drive, Papillion, NE 68046
Phone: 402-593-3141
Fax: 402-593-3145

For more information, please contact:

Trial: NCT02595944

Disease Type: Lung
Status: Open

Trial Information

Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers

Click here for more information

This trial is available at:

Henry Lynch Cancer Center – Bergan
7500 Mercy Road, Suite 1300, Omaha, NE 68124
Phone: 402-393-3110
Fax: 402-393-4499

Methodist Estabrook Cancer Center
8303 Dodge Street, Suite 250, Omaha, NE 68114
Phone: 402-354-8124
Fax: 402-354-8127

Midwest Cancer Center – Legacy
17201 Wright Street, Suite 200, Omaha, NE 68130
Phone: 402-334-4773
Fax: 402-330-7463

Midwest Cancer Center – Papillion
611 Fenwick Drive, Papillion, NE 68046
Phone: 402-593-3141
Fax: 402-593-3145

For more information, please contact:

Trial: NCT02713867

Disease Type: Lung
Status: Open

Trial Information

A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 3 mg/kg Every 2 Weeks vs Nivolumab 6 mg/kg Every 4 Weeks in Subjects with Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer who Received 4 Months of Nivolumab at 3 mg/kg Every 2 Weeks

Click here for more information

This trial is available at:

Methodist Estabrook Cancer Center
8303 Dodge Street, Suite 250, Omaha, NE 68114
Phone: 402-354-8124
Fax: 402-354-8127

Midwest Cancer Center – Legacy
17201 Wright Street, Suite 200, Omaha, NE 68130
Phone: 402-334-4773
Fax: 402-330-7463

Midwest Cancer Center – Papillion
611 Fenwick Drive, Papillion, NE 68046
Phone: 402-593-3141
Fax: 402-593-3145

For more information, please contact:

Trial: NCT02683941

Disease Type: Lung
Status: Open

Trial Information

A Phase 3, Prospective, Randomized, Double-blind, Multi-center Study of the Efficacy and Safety of Lanreotide Autogel/Depot 120 mg Plus BSC vs. Placebo Plus BSC for Tumor Control in Subjects with Well-Differentiated, Metastatic and/or Unresectable Typical or Atypical Lung Neuroendocrine Tumors (Spinet) – Ipsen A-US-52030-328

Click here for more information

This trial is available at:

Methodist Estabrook Cancer Center
8303 Dodge Street, Suite 250, Omaha, NE 68114
Phone: 402-354-8124
Fax: 402-354-8127

Midwest Cancer Center – Legacy
17201 Wright Street, Suite 200, Omaha, NE 68130
Phone: 402-334-4773
Fax: 402-330-7463

Midwest Cancer Center – Papillion
611 Fenwick Drive, Papillion, NE 68046
Phone: 402-593-3141
Fax: 402-593-3145

For more information, please contact:

Trial: NCT02737501

Disease Type: Lung
Status: Open

Trial Information

A Phase 3 Multicenter Open-label Study of Brigatinib (AP26113) Versus Crizotinib in Patients With ALK-positive Advanced Lung Cancer

Click here for more information

This trial is available at:

Methodist Estabrook Cancer Center
8303 Dodge Street, Suite 250, Omaha, NE 68114
Phone: 402-354-8124
Fax: 402-354-8127

Midwest Cancer Center – Legacy
17201 Wright Street, Suite 200, Omaha, NE 68130
Phone: 402-334-4773
Fax: 402-330-7463

Midwest Cancer Center – Papillion
611 Fenwick Drive, Papillion, NE 68046
Phone: 402-593-3141
Fax: 402-593-3145

For more information, please contact:

Trial: NCT02973789

Disease Type: Lung
Status: Pending

Trial Information

LUNAR: Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields)  in Combination With PD-1 Inhibitors or Docetaxel, for Second Line Treatment of Non-small Cell Lung Cancer (NSCLC)

Click here for more information

This trial is available at:

Methodist Estabrook Cancer Center
8303 Dodge Street, Suite 250, Omaha, NE 68114
Phone: 402-354-8124
Fax: 402-354-8127

Midwest Cancer Center – Legacy
17201 Wright Street, Suite 200, Omaha, NE 68130
Phone: 402-334-4773
Fax: 402-330-7463

Midwest Cancer Center – Papillion
611 Fenwick Drive, Papillion, NE 68046
Phone: 402-593-3141
Fax: 402-593-3145

For more information, please contact:

Trial: NCT02906852

Disease Type: Lung
Status: Open

Trial Information

This trial is available at:

Methodist Estabrook Cancer Center
8303 Dodge Street, Suite 250, Omaha, NE 68114
Phone: 402-354-8124
Fax: 402-354-8127

For more information, please contact: